Mirati Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Mirati Therapeutics Inc (MRTX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Mirati Therapeutics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 38M vs 763,203M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+71.8% annualized vs trailing 12 months), vs decelerating (-36.7%) for its tracked peer group.
- Growth: Mirati Therapeutics Inc generated 202.0% revenue growth year over year in Q3 2023, vs -5.4% for its tracked competitors combined.
- Profitability: Its -987.2% net margin compares with 28.6% for the peer group.
- Peer revenue share: Mirati Therapeutics Inc accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.08M compares with $1.02M for the peer group (0.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
MRTX Sales vs. its Competitors, Q3 2023
Mirati Therapeutics Inc reported revenue growth of 201.97 % year on year in Q3 2023, above its competitors' combined revenue change of -5.44 %.
With a net margin of -987.22 %, Mirati Therapeutics Inc reported lower profitability than its competitors (28.63 %).
Mirati Therapeutics Inc generated 0.01 % of the combined sales of its peer group, up from 0.00 % a year earlier.
Mirati Therapeutics Inc vs. its Competitors, Q3 2023
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Mirati Therapeutics Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Mirati Therapeutics Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Mirati Therapeutics Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (95) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (3) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Mirati Therapeutics Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 9.1% year over year, combined, vs 202.0% for Mirati Therapeutics Inc. Mirati Therapeutics Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Mirati Therapeutics Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Mirati Therapeutics Inc | No | Yes | Yes | Yes |
| Competitors combined (316) | ||||
| High-Confidence Competitors (103) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 37.50 % (3 of 8) | 37.50 % (3 of 8) | 50.00 % (4 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
MRTX Stock Performance relative to its Competitors
MRTX Stock Performance relative to High-Confidence Competitors
MRTX Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Gt Biopharma Inc | 282.9% | Outperformed |
| 2 | Adlai Nortye Ltd | 282.9% | Outperformed |
| 3 | Sellas Life Sciences Group Inc | 282.9% | Outperformed |
| 4 | Erasca Inc | 282.9% | Outperformed |
| 5 | Gossamer Bio Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Mirati Therapeutics Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Mirati Therapeutics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Mirati Therapeutics Inc | 3,815.09 | 38.19 |
| Eli Lilly And Company | 1,138,091.20 | 79,665.80 |
| Akari Therapeutics Plc | 976,776.44 | - |
| Johnson and Johnson | 645,965.17 | 99,335.00 |
| Beone Medicines Ltd | 568,469.81 | 6,128.24 |
| Abbvie Inc | 505,868.44 | 64,386.00 |
| SUBTOTAL | 6,475,940.07 | 843,292.08 |
Sign in to see all competitors of Mirati Therapeutics Inc .
Sources: Mirati Therapeutics Inc's official press releases and company reports; CSIMarket.com's market research; and the company reports and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Mirati Therapeutics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Mirati Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from Mirati Therapeutics Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Actinium Pharmaceuticals Inc | Company report | 85% |
| Agentix Corp | Company report | 85% |
| Monopar Therapeutics Inc | Company report | 85% |
| Cadrenal Therapeutics Inc | Company report | 85% |
| Qsam Biosciences Inc | Company report | 85% |
| Shattuck Labs Inc | Company report | 85% |
| Spyre Therapeutics Inc | Company report | 85% |
| Protagonist Therapeutics inc | Company report | 85% |
| Adaptimmune Therapeutics Plc | Company report | 85% |
| AbbVie Inc. | Company report | 85% |
| AstraZeneca plc | Company report | 85% |
| Amgen, Inc. | Company report | 85% |
| Fate Therapeutics Inc | Company report | 85% |
| Sana Biotechnology Inc | Company report | 85% |
| Sellas Life Sciences Group Inc | Company report | 85% |
| Can fite Biopharma Ltd | Company report | 85% |
| Intra cellular Therapies Inc | Company report | 85% |
| Nuvalent Inc | Company report | 85% |
| Cell Source Inc | Company report | 85% |
| Elicio Therapeutics Inc | Company report | 85% |
| Vincerx Pharma Inc | Company report | 85% |
| Gsk Plc | Company report | 85% |
| Allogene Therapeutics Inc | Company report | 85% |
| Pfizer Inc. | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Takeda Pharmaceutical Company Limited | Company report | 85% |
| Gilead Sciences, Inc. | Company report | 85% |
| Sanofi S.A. | Company report | 85% |
| Fusion Pharmaceuticals Inc | Company report | 85% |
| Marker Therapeutics inc | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Corvus Pharmaceuticals, Inc. | Company report | 85% |
| Eli Lilly and Company | Company report | 85% |
| Briacell Therapeutics Corp | Company report | 85% |
| Redwoods Acquisition Corp | Company report | 85% |
| Tradeup Acquisition Corp | Company report | 85% |
| Alx Oncology Holdings Inc | Company report | 85% |
| Candel Therapeutics Inc | Company report | 85% |
| Kura Oncology Inc | Company report | 85% |
| Cue Biopharma Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Mirati Therapeutics Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from Mirati Therapeutics Inc reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.
Mirati Therapeutics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.93 % |
| Merck and Co Inc | Pharmaceutical segment 88.88 % |
| Amgen Inc | Reportable 100.00 % |
| Pfizer Inc | U.S. Commercial Division 52.92 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Mirati Therapeutics Inc .
Mirati Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Mirati Therapeutics Inc | 3,815 | 84,869 | -1,613,062 |
| Eli Lilly And Company | 1,138,091 | 1,593,316 | 534,224 |
| Akari Therapeutics Plc | 976,776 | - | -4,674,667 |
| Johnson and Johnson | 645,965 | 705,504 | 114,311 |
| Beone Medicines Ltd | 568,470 | 510,686 | 54,642 |
| Abbvie Inc | 505,868 | 1,129,579 | 110,807 |
| PEERS TOTAL | 6,472,125 | 1,023,191 | 128,561 |
Sign in to see all peers for Mirati Therapeutics Inc .
Mirati Therapeutics Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 61.21 % |
| Johnson and Johnson | United States 58.90 % |
| Beone Medicines Ltd | United States 51.69 % |
| Merck and Co Inc | EMEA 23.60 % |
| Gilead Sciences Inc | United States 70.78 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Mirati Therapeutics Inc .
Mirati Therapeutics Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (456 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 100.00 % | 42.51 % (avg) | +57.5 pp |
| Operating Margin | -2,002.75 % | industry median | -1,919.3 pp |
| EBITDA Margin | -1,889.02 % | -6.83 % (avg) | -1,882.2 pp |
| Capital Intensity (Capex / Revenue) | 4.81 % | 7.04 % (avg) | -2.2 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Mirati Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (456 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.2x | - |
| EV / EBITDA | - | 15.9x | - |
| P/B | 3.1x | 4.3x | -1.2x |
| Return on Equity | -82.15 % | industry aggregate | -93.61 % |
| Return on Invested Capital | -42.17 % | -4.07 % (avg) | -38.10 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Mirati Therapeutics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2015 | 2016 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - |
| Operating Margin | - | - | -6,659.79 % | - | - | -6,107.98 % |
| Return on Invested Capital | -34.62 % | -56.28 % | -28.21 % | -23.11 % | -23.10 % | -33.15 % |
| P/E | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Mirati Therapeutics Inc's Strategic Group Map
Every company in Mirati Therapeutics Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Mirati Therapeutics Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Mirati Therapeutics Inc's trailing-12-month revenue growth of 223.6% and operating margin of -2,002.8% compares with an average of 38.2% growth and -941.2% margin across its 8 closest peers by combined growth, margin and ROIC -- Mirati Therapeutics Inc sits above that peer average on growth and below it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Mirati Therapeutics Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 4.81 % vs industry average 7.04 % (see Profitability & Cost Structure above) |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments. Supplier power and buyer power are not assessed here -- see Mirati Therapeutics Inc's dedicated Suppliers and Customers pages for concentration data; threat of substitutes has no systematic data source in this system and is not estimated.
Mirati Therapeutics Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Mirati Therapeutics Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Mirati Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+71.8% annualized vs trailing 12 months).
Weaknesses
- Operating margin 1,919.3 points below the industry median.
- Return on equity 93.6 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (43.70 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-36.7% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Mirati Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Mirati Therapeutics Inc | 1.54 | 6.95 | - |
| Eli Lilly And Company | 0.20 | 1.48 | 1.59 |
| Akari Therapeutics Plc | 0.23 | 0.26 | 0.04 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Beone Medicines Ltd | 2.30 | 3.16 | 0.23 |
| Abbvie Inc | 0.16 | 0.75 | - |
Sign in to see all peers for Mirati Therapeutics Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Mirati Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Mirati Therapeutics Inc | Q3 2023 | +202.0 % | - |
| Eli Lilly And Company | Q2 2026 | +47.7 % | +25.3 % |
| Akari Therapeutics Plc | Q1 2026 | - | - |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Beone Medicines Ltd | Q2 2026 | +29.7 % | +151.3 % |
| Abbvie Inc | Q2 2026 | +10.2 % | +284.3 % |
| PEERS TOTAL | +10.6 % | -11.1 % |
Sign in to see all peers for Mirati Therapeutics Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Mirati Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Mirati Therapeutics Inc | Q3 2023 | - | -97.1 % |
| Eli Lilly And Company | Q2 2026 | +33.5 % | +72.8 % |
| Akari Therapeutics Plc | Q1 2026 | - | - |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Beone Medicines Ltd | Q2 2026 | +6.4 % | -57.0 % |
| Abbvie Inc | Q2 2026 | -1.3 % | +19.7 % |
Sign in to see all peers for Mirati Therapeutics Inc .
Mirati Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Mirati Therapeutics Inc | - | - | - |
| Eli Lilly And Company | 21.97% | 33.95% | 92.54% |
| Akari Therapeutics Plc | - | - | - |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Beone Medicines Ltd | 7.82% | 10.32% | 14.24% |
| Abbvie Inc | 4.68% | 9.11% | - |
Sign in to see all peers for Mirati Therapeutics Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Mirati Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Mirati Therapeutics Inc | - | 99.90 |
| Eli Lilly And Company | 42.75 | 14.29 |
| Akari Therapeutics Plc | - | - |
| Johnson and Johnson | 39.91 | 6.50 |
| Beone Medicines Ltd | 858.25 | 92.76 |
| Abbvie Inc | 80.69 | 7.86 |
| PEERS AVERAGE | 61.54 | 7.68 |
Sign in to see all peers for Mirati Therapeutics Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.